Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 261

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 1B
Chunk 261
---
324,805

    539,106

    Total liabilities and stockholders’ equity
     
    $
    1,434,592

    $
    635,353

See the accompanying notes to these consolidated financial statements. 

F-4

CRINETICS PHARMACEUTICALS, INC.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data) 

    Year ended December 31,

    2024

    2023

    2022

    Revenues
     
    $
    1,039

    $
    4,013

    $
    4,737

    Operating expenses:

    Research and development

    240,156

    168,527

    130,225

    General and administrative

    99,737

    58,094

    42,394

    Total operating expenses

    339,893

    226,621

    172,619

    Loss from operations

    (338,854
    )

    (222,608
    )

    (167,882
    )

    Other income (expense):

    Interest income

    41,435

    13,436

    4,317

    Change in fair value of derivative asset

    —

    —

    600

    Other income (expense), net

    (519
    )

    (159
    )

    57

    Total other income, net

    40,916

    13,277

    4,974

    Loss before equity method investment

    (297,938
    )

    (209,331
    )

    (162,908
    )

    Loss on equity method investment

    (470
    )

    (5,198
    )

    (1,010
    )

    Net loss
     
    $
    (298,408
    )
     
    $
    (214,529
    )
     
    $
    (163,918
    )

    Net loss per share:

    Net loss per share - basic and diluted
     
    $
    (3.69
    )
     
    $
    (3.69
    )
     
    $
    (3.15
    )

    Weighted average shares - basic and diluted

    80,783

    58,071

    51,982